Javid Hasanzade

Work experience

• 1997–1998 — National Oncology Center, Baku, Azerbaijan — physician, internal medicine specialist.

• 1998–2001 — National Army of the Republic of Azerbaijan — physician, head of the battalion medical point.

• 2001–2013 — National Oncology Center, Baku, Azerbaijan — oncologist.

• 2013–2015 — Balkaly Hospital, Adana Çukurova University Medical Faculty (Bone Marrow Transplant Center), Adana, Turkey — oncologist.

• 2015–2016 — Ganja International Hospital, Ganja, Azerbaijan — oncologist.

• 2017–2022 — Medicana International Hospital, Istanbul, Turkey — oncologist.

• 2022 — Healthis Assistance, physician-consultant, International Patient Department.

• 2024–present — Orhun Medical, Almaty, Kazakhstan — medical oncologist.

Education

• 1990–1996 — Azerbaijan State Medical University, Baku.

• 1996–1998 — National Oncology Center, Baku, Candidate of Medical Sciences.

• 2002–2009 — National Oncology Center, Baku, Candidate of Medical Sciences in Oncology.

• 04–05.2015 — MD Anderson Cancer Center, USA, leukemia research.

• 2013–2015 — Adana Çukurova University, Medical Faculty, Balkaly Hospital, Bone Marrow Transplantation Department, Turkey.

• 22.01–22.04.2009 — Bone Marrow Transplantation Department, Bayındır Hospital, Ankara, Turkey.

Membership in Professional Organizations

• Turkish Society of Hematology, European Society for Blood and Marrow Transplantation (EBMT).

Publications

• Use of Gemzar in the treatment of metastatic gastric cancer, Azerbaijan Journal of Oncology and Related Sciences, 2001, 7, pp.29-31. 3 pages R.S.Zeynalov, N.R.Dadashova, I.N.Musaev.

• R.S.Zeynalov, S.R.Giyasbayli, N.R.Dadashova, I.N.Musaev, A.A.Abdullayev. Capecitabine in combination with leucovorin in metastatic gastric cancer treatment. Proceedings of the memorial scientific-practical conference dedicated to the 100th anniversary of Prof. M.M.Alikishibekov, 2001, p.21. 1 page.

• R.S.Zeynalov, S.R.Giyasbayli, N.R.Dadashova, I.N.Musaev, R.N.Orujlu. Toxic effects of Capecitabine in the treatment of disseminated gastric and breast cancer. 2001, p.22. 1 page.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev, E.E.Maxmudova. Effectiveness of Capecitabine as first-line chemotherapy in elderly patients with disseminated breast cancer. Azerbaijan Journal of Oncology and Related Sciences, 2002, 9, pp.30-33. 4 pages.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev. Effectiveness of chemotherapy regimens including Capecitabine in disseminated gastric cancer treatment. 2002, 9, pp.88-90. 3 pages.

• R.S.Zeynalov, I.N.Musaev. Effectiveness of chemotherapy regimen including Gemcitabine in non-small cell lung cancer patients. 2003, p.21. 1 page.

• R.S.Zeynalov, I.N.Musaev. Effectiveness of Capecitabine in breast cancer patients with liver metastases. 2003, p.57. 3 pages.

• R.S.Zeynalov, I.N.Musaev. Comparative effectiveness of Capecitabine and Paclitaxel in disseminated breast cancer resistant to anthracyclines. 2003, p.60. 3 pages.

• R.S.Zeynalov, I.N.Musaev, N.R.Dadashova. Effectiveness of two chemotherapy regimens including Capecitabine and Doxorubicin in breast cancer patients with liver metastases. 2003, 10, pp.51-54. 4 pages.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev. Use of Fareston in disseminated ovarian cancer treatment. 2004, p.405. 1 page.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev, E.Y.Maxmudova. Effectiveness of hormone therapy in disseminated breast cancer treatment. 2004, p.406. 1 page.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev. Toxic profile of chemotherapy regimens including Capecitabine in breast cancer with liver metastases. 2004, p.406. 1 page.

• R.S.Zeynalov, N.R.Dadashova, I.N.Musaev. Comparative effectiveness of three chemotherapy regimens in disseminated gastric cancer. 2004, p.406. 1 page.

• R.S.Zeynalov, I.N.Musaev. Drug treatment of various morphological types of disseminated gastric cancer. 1st Congress of Oncologists of Uzbekistan, p.429. 1 page.

• R.S.Zeynalov, I.N.Musaev. Quality of life of patients with disseminated gastric cancer receiving antitumor chemotherapy. 1st Congress of Oncologists of Uzbekistan, p.430. 1 page.

• R.S.Zeynalov, I.N.Musaev. Use of Zometa in patients with bone metastases of malignant tumors. 1st Congress of Oncologists of Uzbekistan, p.471. 1 page.

• R.S.Zeynalov, S.R.Giyasbayli, N.R.Dadashova, I.N.Musaev. Effectiveness of Toremifene and Letrozole in disseminated breast cancer. European Journal of Cancer, abstract book, Paris, 2005, v.3, No2, p.132. 1 page.

• D.A.Aliyev, R.S.Zeynalov, R.D.Dzhafyarov, I.K.Kazymov, T.Y.Nyazyafov, S.R.Rashimova, I.N.Musaev, N.R.Dadashova. 3-year survival of stage II breast cancer patients receiving adjuvant hormone therapy with Toremifene (primary results). 2005, v.3, No2, p.110. 1 page.

• D.A.Aliyev, R.D.Dzhafyarov, I.K.Kazymov, R.S.Zeynalov, I.N.Musaev, N.R.Dadashova. Effectiveness of Toremifene in diffuse mastopathy treatment. 2005, v.3, No2, p.106. 1 page.

• D.A.Aliyev, R.S.Zeynalov, N.R.Dadashova. Modern antimetabolites Capecitabine and Gemzar in disseminated gastric cancer treatment. 2005, s.317. 15 pages.

• D.A.Aliyev, R.S.Zeynalov, I.N.Musaev, T.A.Mirzyabayov. Comparative effectiveness of Capecitabine and Paclitaxel in anthracycline-resistant breast cancer with liver metastases. 2009, 1, pp.61-64. 4 pages.

• R.S.Zeynalov, I.N.Musaev. Current state of breast cancer liver metastases treatment. 2009, 9, pp.16-20. 5 pages.

• R.S.Zeynalov, I.N.Musaev. Effectiveness of Capecitabine in breast cancer patients with liver metastases. ‘GEORGIAN MEDICAL NEWS’, 2009, 7-8, pp.13-16. 4 pages.

• R.S.Zeynalov. Comparison of toxic effects of DKAPLV and AT regimens in breast cancer patients with liver metastases. 2009, s.6, pp.92-94. 3 pages.

• E.Abdullayev. Assessment of dynamic HBV-DNA levels in patients undergoing hematopoietic stem cell transplantation with high risk of HBV infection. 2015, S577-S578. 1 page.

• E.Abdullayev. Squamous cell breast cancer. Electronic poster at VII Turkish Society of Medical Oncology, TTOP (2018), S1-82.EP-114. 1 page.